[go: up one dir, main page]

NO20063230L - CRF receptorantagonister og fremgangsmater for fremstilling derav - Google Patents

CRF receptorantagonister og fremgangsmater for fremstilling derav

Info

Publication number
NO20063230L
NO20063230L NO20063230A NO20063230A NO20063230L NO 20063230 L NO20063230 L NO 20063230L NO 20063230 A NO20063230 A NO 20063230A NO 20063230 A NO20063230 A NO 20063230A NO 20063230 L NO20063230 L NO 20063230L
Authority
NO
Norway
Prior art keywords
crf receptor
receptor antagonists
methods
preparation
crf
Prior art date
Application number
NO20063230A
Other languages
English (en)
Inventor
Deborah Slee
Zhiyong Luo
John Edward Tellew
John Williams
Xiaohu Zhang
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20063230L publication Critical patent/NO20063230L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives CRF reseptorantagonister som firmer anvendelse ved behandling av et antall forstyrrelser inkludert behandling av forstyrrelser som manifesterer hypersekresjon av CRF i varmblodige dyr, for eksempel slag. CRF reseptorantagonistene har formel (I) inkludert stereoisomerer, prodmgs og farmasøytisk akseptable salter derav, der RI, R2, R3, Y, Ar og Het er som angitt i beskrivelsen. Det beskrives videre preparater irmeholdende en CRF reseptorantagonist i kombinasjon med en farmasøytisk akseptabel bærer, så vel som fremgangsmåter for anvendelse derav.
NO20063230A 2003-12-22 2006-07-11 CRF receptorantagonister og fremgangsmater for fremstilling derav NO20063230L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22
PCT/IB2004/004234 WO2005063755A1 (en) 2003-12-22 2004-12-20 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
NO20063230L true NO20063230L (no) 2006-09-12

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063230A NO20063230L (no) 2003-12-22 2006-07-11 CRF receptorantagonister og fremgangsmater for fremstilling derav

Country Status (19)

Country Link
US (1) US7737154B2 (no)
EP (1) EP1697374B1 (no)
JP (1) JP4926720B2 (no)
KR (1) KR20070009537A (no)
CN (1) CN1938309B (no)
AR (1) AR046967A1 (no)
AU (1) AU2004309168B2 (no)
BR (1) BRPI0417943A (no)
CA (1) CA2550948A1 (no)
IL (1) IL176350A0 (no)
IS (1) IS8526A (no)
MA (1) MA29984B1 (no)
MY (1) MY143499A (no)
NO (1) NO20063230L (no)
NZ (1) NZ547990A (no)
RU (1) RU2394035C2 (no)
TW (1) TW200530242A (no)
WO (1) WO2005063755A1 (no)
ZA (1) ZA200604574B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
ES2326827T3 (es) * 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
NZ575572A (en) * 2006-09-20 2011-10-28 Lilly Co Eli Thiazole pyrazolopyrimidines as crf1 receptor antagonists
CN101516886B (zh) * 2006-09-20 2012-02-29 伊莱利利公司 噻吩吡唑并嘧啶化合物
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
CN102066331A (zh) * 2008-04-21 2011-05-18 阿尔比马尔公司 制备n-烷基吡唑的方法
WO2011095450A1 (en) * 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2014067962A1 (de) 2012-10-31 2014-05-08 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
PT3130592T (pt) * 2014-04-10 2019-11-21 Hubei Bio Pharmaceutical Industrial Tech Institute Inc Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp
CA3064464A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
MX2023001181A (es) * 2020-07-27 2023-06-16 Esfam Biotech Pty Ltd Compuestos.
CA3188730A1 (en) 2020-08-12 2022-02-17 Christopher Barnes Methods and compositions for treating polycystic ovary syndrome
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1090189C (zh) * 1996-02-07 2002-09-04 詹森药业有限公司 吡唑并嘧啶类化合物
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
US6313124B1 (en) * 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
IL127566A0 (en) 1996-08-28 1999-10-28 Pfizer Substituted 6,5-hetero- bicyclic derivatives
EP0984692A4 (en) * 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
CN1137123C (zh) * 1998-01-28 2004-02-04 杜邦药品公司 吡咯并三嗪和嘧啶化合物
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
OA12049A (en) 1999-09-30 2006-05-02 Neurogen Corp Amino substituted pyrazoloÄ1,5,-aÜ-1,5-pyrimidinesand pyrazoloÄ1,5,-aÜ-1,3,5-triazines.
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
JP2004528349A (ja) * 2001-04-30 2004-09-16 グラクソ　グループ　リミテッド 副腎皮質刺激ホルモン放出因子（ｃｒｆ）のアンタゴニストとしての縮合ピリミジン類
ATE397609T1 (de) * 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
ES2285409T3 (es) * 2003-01-16 2007-11-16 Sb Pharmco Puerto Rico Inc Derivados pirrol(2,3-b)piridina sustituidos con heteroarilo como antagonistas del receptor de crf.
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
WO2005063756A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
ES2326827T3 (es) * 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
KR20070009537A (ko) 2007-01-18
JP2007515472A (ja) 2007-06-14
JP4926720B2 (ja) 2012-05-09
ZA200604574B (en) 2007-11-28
CN1938309A (zh) 2007-03-28
AU2004309168A1 (en) 2005-07-14
IL176350A0 (en) 2006-10-05
AU2004309168B2 (en) 2009-04-23
IS8526A (is) 2006-07-11
US20070287705A1 (en) 2007-12-13
WO2005063755A1 (en) 2005-07-14
TW200530242A (en) 2005-09-16
AR046967A1 (es) 2006-01-04
CA2550948A1 (en) 2005-07-14
BRPI0417943A (pt) 2007-04-17
RU2006126675A (ru) 2008-01-27
EP1697374B1 (en) 2012-08-29
EP1697374A1 (en) 2006-09-06
CN1938309B (zh) 2011-11-09
RU2394035C2 (ru) 2010-07-10
NZ547990A (en) 2010-04-30
MA29984B1 (fr) 2008-12-01
MY143499A (en) 2011-05-31
US7737154B2 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
HRP20080666T3 (en) Cgrp receptor antagonists
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
MXPA05009508A (es) Derivados de nicotinamida 6-substituida como antagonistas de receptor opioide.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
NO20070445L (no) Pyrimidinderivater.
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TW200626599A (en) CRF receptor antagonists and methods relating thereto
SG154443A1 (en) Piperidine derivatives as nk1 antagonists
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
MX2007007152A (es) Antagonista de naurocinina-1 con anillo en puente.
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20035148D0 (no) Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister
TW200514785A (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
ATE250058T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
TW200633997A (en) Substituted heterocyclic compounds and thrombopoietin receptor activators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application